SCHEMBL2303433

SCHEMBL2303433

CCCC(c1ccc(O)c(O)c1)c1cc(O)ccc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 7/20 0.41
KDM4E B2RXH2 6/20 0.41
MAPK1 P28482 3/20 0.41
SHBG P04278 1/20 0.41
MAPT P10636 5/20 0.39
RECQL P46063 5/20 0.39
KMT2A Q03164 4/20 0.39
APEX1 P27695 4/20 0.39
ADRB2 P07550 4/20 0.39
MEN1 O00255 3/20 0.39
PTGS2 P35354 3/20 0.39
CYP2D6 P10635 2/20 0.39
ADRB1 P08588 2/20 0.39
CYP3A4 P08684 2/20 0.39
ADRA2A P08913 2/20 0.39
ADORA3 P0DMS8 2/20 0.39
ADRB3 P13945 2/20 0.39
DRD2 P14416 2/20 0.39
ADRA2B P18089 2/20 0.39
ADRA2C P18825 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4596473 0.86 ALOX15 (0.49) TDP1MAPTKMT2AMEN1PTGS2
SCHEMBL2305253 0.84 TDP1 (0.49) TDP1KDM4EMAPK1SHBGMAPT
SCHEMBL2306283 0.78 HKDC1 (0.46) TDP1KDM4EMAPK1SHBGMAPT
SCHEMBL2311556 0.78 SHBG (0.47) TDP1KDM4EMAPK1SHBGMAPT
SCHEMBL9192736 0.76 LMNA (0.48) TDP1KDM4EMAPK1MAPTKMT2A
SCHEMBL10335356 0.76 TYR (0.48) TDP1MAPTRECQLKMT2ACYP2D6
SCHEMBL4596232 0.75 ALDH1A1 (0.47) TDP1KDM4EMAPK1MAPTRECQL
SCHEMBL7201794 0.75 THRA (0.44) TDP1KDM4EMAPTRECQLKMT2A
SCHEMBL4659818 0.74 TYR (0.42) TDP1KDM4EMAPK1MAPTRECQL
SCHEMBL7950538 0.74 RORC (0.47) TDP1KDM4EMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3044593-A1 CANCER THERAPY Triact Therapeutics, Inc. (US) 2016-07-20 EP claimed
WO-2015035410-A1 CANCER THERAPY TRIACT THERAPEUTIC, INC. (US) 2015-03-12 WO claimed
EP-2349235-A1 USE OF CATECHOLIC BUTANE DERIVATIVES IN CANCER THERAPY Triact Therapeutics, Inc. (US) 2011-08-03 EP claimed
WO-2010054264-A1 USE OF CATECHOLIC BUTANE DERIVATIVES IN CANCER THERAPY TRIACT THERAPEUTICS, INC. (US) 2010-05-14 WO claimed
WO-1995000129-A1 TREATMENT OF MULTIDRUG RESISTANT DISEASES CHEMEX PHARMACEUTICALS INC. (US) 1995-01-05 WO claimed
EP-3044593-A1 CANCER THERAPY Triact Therapeutics, Inc. (US) 2016-07-20 EP disclosed
EP-2961412-A1 CANCER THERAPY Triact Therapeutics, Inc. (US) 2016-01-06 EP disclosed
WO-2015035410-A1 CANCER THERAPY TRIACT THERAPEUTIC, INC. (US) 2015-03-12 WO disclosed
WO-2014134202-A1 CANCER THERAPY TRIACT THERAPEUTICS, INC. (US) 2014-09-04 WO disclosed
EP-2349235-A1 USE OF CATECHOLIC BUTANE DERIVATIVES IN CANCER THERAPY Triact Therapeutics, Inc. (US) 2011-08-03 EP disclosed
WO-2010054264-A1 USE OF CATECHOLIC BUTANE DERIVATIVES IN CANCER THERAPY TRIACT THERAPEUTICS, INC. (US) 2010-05-14 WO disclosed
WO-1995000129-A1 TREATMENT OF MULTIDRUG RESISTANT DISEASES CHEMEX PHARMACEUTICALS INC. (US) 1995-01-05 WO disclosed
EP-0288534-A4 COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC. CHEMEX PHARMACEUTICALS INC (US) 1989-02-23 EP disclosed
EP-0288534-A1 COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC. CHEMEX PHARMACEUTICALS INC (US) 1988-11-02 EP disclosed
WO-1988003026-A1 COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC CHEMEX PHARMACEUTICALS, INC. (US) 1988-05-05 WO disclosed